Eumentis Therapeutics
EuMentis Therapeutics is committed to leading innovation in neuropsychiatric diseases by developing therapies that target specific CNS circuits with validated mechanisms of action. Their mission is to improve health and well-being for individuals affected by neuropsychiatric disorders, with a focus on schizophrenia. Their lead product, EM-221, is a novel PDE10A inhibitor aimed at providing better efficacy and tolerability, addressing both positive and negative symptoms of schizophrenia.
Industries
Nr. of Employees
small (1-50)
Eumentis Therapeutics
Products
Clinical-stage PDE10A inhibitor candidate (lead compound)
A selective, striatum-concentrated PDE10A inhibitor developed to enhance cyclic nucleotide signaling and modulate dopamine pathways for treatment of schizophrenia and other CNS disorders; advanced through preclinical development, with IND clearance to support clinical trials.
EM-221
An innovative pipeline-in-a-product targeting the phosphodiesterase 10A (PDE10A) enzyme to enhance cyclic nucleotide signaling and balance dopamine pathways for the treatment of schizophrenia and Parkinson's LID.
Clinical-stage PDE10A inhibitor candidate (lead compound)
A selective, striatum-concentrated PDE10A inhibitor developed to enhance cyclic nucleotide signaling and modulate dopamine pathways for treatment of schizophrenia and other CNS disorders; advanced through preclinical development, with IND clearance to support clinical trials.
EM-221
An innovative pipeline-in-a-product targeting the phosphodiesterase 10A (PDE10A) enzyme to enhance cyclic nucleotide signaling and balance dopamine pathways for the treatment of schizophrenia and Parkinson's LID.
Expertise Areas
- Neuropsychiatric drug development
- Clinical trial management (Phase 1–2)
- Regulatory submissions (IND) and FDA interactions
- Mechanism-driven CNS therapeutic design
Key Technologies
- Phosphodiesterase 10A (PDE10A) inhibition
- CNS circuit-targeted pharmacology
- Mechanism-based modulation of cyclic nucleotide signaling
- Small-molecule therapeutic design for CNS
News & Updates
Company expects to initiate Phase 2 study in 2H 2025.
Company expects to initiate Phase 2 study in 2H 2025.